NUS researchers pioneer DNA-tagged gold nanoparticles for targeted cancer treatment

January 24, 2025 06:55 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Using DNA barcoding, the novel technique tracks and optimises gold nanoparticles for precise drug delivery to tumours, advancing cancer therapies that are safer and more effective

SINGAPORE, Jan. 24, 2025 /PRNewswire/ -- A team of researchers from the National University of Singapore (NUS) has developed a novel method to enhance the precision of cancer treatment using gold nanoparticles tagged with DNA barcodes.

Led by Assistant Professor Andy Tay from the Department of Biomedical Engineering in the College of Design and Engineering and Institute of Health Innovation & Technology at NUS, the study demonstrates how gold nanoparticles of specific shapes, such as triangles, excel in delivering therapeutic nucleic acids and heating tumour cells during photothermal therapy. These findings uncover the distinct preferences of tumour cells for certain nanoparticle configurations, which could enable the development of personalised cancer treatments that are safer and more effective.

The team's novel technique, detailed in a paper published in Advanced Functional Materials on 24 November 2024, enables high-throughput screening of nanoparticle shapes, sizes and modifications, reducing associated screening costs. Beyond cancer treatment, the method has broader therapeutic applications, including RNA delivery and targeting diseases at the organ-specific level.

Size and shape matter

Gold is more than just bling. When reduced to about one-thousandth the width of human hair, gold nanoparticles shine as therapeutic agents for cancer therapy. For instance, specks of the precious metal are used in photothermal therapy, where particles delivered to the tumour site convert specific wavelengths of light to heat, killing surrounding cancer cells. Gold nanoparticles can also serve as messengers to deliver drugs directly to specific locations within a tumour.

"But for these gold nanoparticles to work, they first need to get into the targeted sites successfully," said Asst Prof Tay. "Think of it as a delivery person with a special key — if the key doesn't fit the lock, the package won't get through."

Achieving this level of precision requires finding the right nanoparticle design — its shape, size and surface properties must align with the preferences of target cells. However, existing screening methods to pinpoint optimal designs are akin to searching for needles in a haystack. Moreover, these methods often overlook the preferences of different cell types within a tumour, from immune to endothelial to cancer cells.

To tackle these challenges, the NUS researchers turned to DNA barcoding. Each nanoparticle is tagged with a unique DNA sequence, with which the researchers could tag and track individual designs, much like registering a parcel to be shipped by post in a delivery system. Importantly, these barcodes enabled the team to monitor multiple nanoparticle designs simultaneously in vivo, as their sequences could be easily extracted and analysed to locate the nanoparticles' whereabouts within the body.

"We used thiol-functionalisation to securely anchor the DNA barcodes to the surface of the gold nanoparticles. This ensures the barcodes remain stable, resistant to enzymatic degradation and do not interfere with cellular uptake," said Asst Prof Tay, highlighting an important novelty of the team's work.

To demonstrate this, the researchers prepared nanoparticles in six different shapes and sizes, where their distribution and uptake across various cell types were monitored. They found that round nanoparticles, despite showing poor uptake in cell culture studies, were excellent in targeting tumours in preclinical models as they were less likely to be eliminated by the immune system. On the other hand, triangular nanoparticles excelled in both in vitro and in vivo tests, resulting in high cellular uptake and strong photothermal properties.

Making cancer treatments safer

The team's work shines a light on nanoparticle interactions in biological systems and the need to bridge discrepancies between in vitro and in vivo findings, as evidenced by those revealed by the round gold nanoparticles. These insights could guide the development of shape-morphing nanoparticles or intermediate designs tailored to optimise different stages of drug delivery.

Additionally, the research also illuminates the untapped potential of exploring nanoparticle shapes beyond spheres, which dominate those approved by the U.S. Food and Drug Administration. The researchers' DNA barcoding method could also extend to screen other inorganic nanoparticles such as iron and silica in vivo, broadening the scope for drug delivery and precision medicine.

Looking ahead, the researchers are expanding their nanoparticle library to include 30 designs to identify candidates capable of targeting subcellular organelles. Suitable ones will then be tested for their efficacy in gene silencing and photothermal therapy for breast cancer. Asst Prof Tay also shared that the findings could significantly improve our understanding of RNA biology and advance RNA delivery techniques, which are increasingly being applied in therapeutics for treatment of various diseases.

"We have addressed a key challenge in cancer treatment — delivering drugs specifically to cancer tissues with greater efficiency," said Asst Prof Tay. "The Achilles' heel of existing nanoparticle-based drugs is their assumption of uniform delivery across all organs, but the reality is that different organs respond differently. Designing optimally-shaped nanoparticles for organ-specific targeting enhances the safety and efficacy of nanotherapeutics for cancer treatment — and beyond."

Read more at: https://news.nus.edu.sg/dna-tagged-gold-nanoparticles-for-targeted-cancer-treatment/


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.